At Fortress Biotech, our diversified product pipeline includes over 25 candidates in various phases of pre-clinical and clinical development. These product candidates are developed in collaboration with our partner companies and span several large-market therapeutic areas, including oncology, rare diseases, gene therapy and more. In addition, Fortress has several marketed dermatology products.
58% Journey Medical Corporation
Acne
58% Journey Medical Corporation
Acne
58% Journey Medical Corporation
Fungal Infections
58% Journey Medical Corporation
Eczema
58% Journey Medical Corporation
Wounds
58% Journey Medical Corporation
Recalcitrant Nodular Acne
58% Journey Medical Corporation
58% Journey Medical Corporation
58% Journey Medical Corporation
CONTRAINDICATIONS AND WARNINGS
Accutane® must not be used by patients who are or may become pregnant. There is an extremely high risk that severe birth defects will result if pregnancy occurs while taking Accutane in any amount, even for short periods of time. Potentially any fetus exposed during pregnancy can be affected. There are no accurate means of determining whether an exposed fetus has been affected.
CUTX-101 is a copper histidinate injection for the treatment of Menkes disease.
View Clinical Trial View Clinical TrialMenkes Disease
Menkes disease is an X-linked genetic disorder of copper transport caused by mutations of the ATP7A gene. Copper is an essential trace element required for human development and health. In Menkes disease, patients are born without the ability to absorb copper from diet, leading to severe developmental delays and significant neurological symptoms. Without treatment, Menkes disease could lead to death by three years of age. There is currently no FDA-approved therapy for the treatment of Menkes disease.
72% Cyprium; 4.5% Royalty | 2.5% Equity Dividend
MB-107 is a novel lentiviral gene therapy intended for the treatment of X-linked severe combined immunodeficiency (XSCID).
View Clinical Trial View Clinical TrialNewly Diagnosed X-Linked Severe Combined Immunodeficiency (XSCID)
XSCID, also known as bubble boy disease, is the most common form of severe combined immunodeficiency, affecting approximately one in 225,000 newborns in the U.S. per year. There are also ~400 patients living with XSCID post-transplant in the U.S. and ~650 patients living with XSCID post-transplant in high- and mid-income ex-U.S. countries.
17% Mustang; 4.5% Royalty | 2.5% Equity Dividend
MB-207 is a novel lentiviral gene therapy intended for the treatment of X-linked severe combined immunodeficiency (XSCID).
View Clinical Trial View Clinical TrialPreviously Transplanted X-Linked Severe Combined Immunodeficiency (XSCID)
XSCID, also known as bubble boy disease, is the most common form of severe combined immunodeficiency, affecting approximately one in 225,000 newborns in the U.S. per year. There are also ~400 patients living with XSCID post-transplant in the U.S. and ~650 patients living with XSCID post-transplant in high- and mid-income ex-U.S. countries.
17% Mustang; 4.5% Royalty | 2.5% Equity Dividend
Cosibelimab is a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 (PD-1) and B7.1 receptors.
View Clinical TrialcSCC, NSCLC
Cutaneous squamous cell carcinoma (cSCC)
Cutaneous squamous cell carcinoma (cSCC) is the second most common type of skin cancer in the United States. cSCC starts in squamous cells within the surface of the skin, and upon progression, can invade deeper layers of the skin or spread to lymph nodes or other parts of the body. Surgery is the first option for patients with cSCC. In advanced stages, some patients will be treated with radiation or systemic drug therapy; however, certain patients may not be able to be cured with surgery or radiation. It is estimated that 7,000 patients in the United States die each year from cSCC.
Non-small cell lung cancer (NSCLC)
Lung cancer is the leading cause of cancer death among men and women. There are two main types of lung cancer: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The American Cancer Society estimates that roughly 80% to 85% of lung cancers are NSCLC. Approximately 20% of newly diagnosed NSCLC patients have activating mutations in EGFR, which can be selectively targeted with an EGFR inhibitor.
19% Checkpoint; 4.5% Royalty | 2.5% Equity Dividend
Olafertinib is a small-molecule, targeted anti-cancer agent for the treatment of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
View Clinical TrialFrontline NSCLC with EGFR Mutations
Lung cancer is the leading cause of cancer death among men and women. There are two main types of lung cancer: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The American Cancer Society estimates that roughly 80% to 85% of lung cancers are NSCLC. Approximately 20% of newly diagnosed NSCLC patients have activating mutations in EGFR, which can be selectively targeted with an EGFR inhibitor.
19% Checkpoint; 4.5% Royalty | 2.5% Equity Dividend
CAEL-101 is a first-in-class anti-amyloid antibody designed to improve organ function by reducing or eliminating amyloid deposits in patients with amyloid light chain (AL) amyloidosis.
View Clinical Trial View Clinical Trial View Clinical TrialAL Amyloidosis
AL amyloidosis is a rare systemic disorder caused by an abnormality of plasma cells in the bone marrow. Misfolded amyloid proteins produced by plasma cells cause buildup in and around tissues, nerves and organs, gradually affecting their function. This can cause progressive and widespread organ damage and high mortality rates.
42% Caelum
DFD-29 program (Modified Release Minocycline Capsules) is being evaluated for the treatment of inflammatory lesions of rosacea. This program is a collaboration between Dr. Reddy’s Laboratories, Ltd. (“Dr. Reddy’s”) and Journey Medical Corporation and currently being sponsored by Dr. Reddy’s.
Rosacea
Rosacea is a chronic, relapsing, diverse skin condition that most commonly presents with symptoms such as deep facial redness, spider veins (telangiectasia) and acne-like inflammatory lesions (papules and pustules). Based on research in the British Journal of Dermatology, it is estimated that 415 million people suffer with rosacea worldwide.1 Rosacea is most frequently seen in adults between 30 and 50 years of age. Surveys conducted by The National Rosacea Society report more than 90 percent of rosacea patients said their condition had lowered their self-confidence and self-esteem, and 41 percent reported that it had caused them to avoid public contact or cancel social engagements. Among rosacea patients with severe symptoms, 88 percent said the disorder had adversely affected their professional interactions, and 51 percent said they had missed work because of their condition.
1. Gether L, Overgaard LK, Egeberg A, Thyssen JP. Incidence and prevalence of rosacea: a systematic review and meta-analysis. Br J Dermatol 2018 Feb 25. doi: 10.1111/bjd.16481
58% Journey Medical Corporation
Triplex is a universal, multi-antigen T-cell immunotherapeutic vaccine for controlling cytomegalovirus (CMV) in stem cell and solid organ transplant recipients.
View Clinical Trial View Clinical Trial View Clinical TrialCytomegalovirus (CMV)
CMV is a common virus that is typically asymptomatic in healthy individuals but can cause life-threatening disease in those with weakened or uneducated immune systems. Patients undergoing allogeneic stem cell and solid organ transplantation are at particularly high risk of experiencing complications associated with CMV.
CMV can be transmitted to seronegative transplant recipients through infected donor grafts or reactivated in seropositive transplant recipients (particularly those with low baseline immunity) as a result of their immune-suppressed condition. In either instance, CMV can cause severe and life-threatening complications, including pneumonia, gastroenteritis and retinitis.
82% Helocyte; 4.5% Royalty
CEVA 101 Pediatric is a clinical-stage cell therapy for the treatment of severe traumatic brain injury (TBI) in children.
View Clinical TrialTraumatic Brain Injury (TBI)
Pediatric severe TBIs are the leading cause of death and disability in children ages 1-14 years old. There are no effective therapies to treat secondary brain injury and the post-injury response of central nervous system apoptosis and neuroinflammation.
78% Cellvation; 4.5% Royalty | 2.5% Equity Dividend
CEVA 101 Adult is a clinical-stage cell therapy for the treatment of severe traumatic brain injury (TBI) in adults.
View Clinical TrialTraumatic Brain Injury (TBI)
TBIs are associated with 33% of all trauma-related deaths. There are no effective therapies to treat secondary brain injury and the post-injury response of central nervous system apoptosis and neuroinflammation.
78% Cellvation; 4.5% Royalty | 2.5% Equity Dividend
IV Tramadol is intended for the management of moderate to moderately severe postoperative pain.
View Clinical Trial View Clinical Trial View Clinical TrialPost-Surgical Acute Pain
Many patients who undergo surgical procedures experience severe postoperative pain. IV Tramadol is being developed as a potential treatment for pain management following surgery, including abdominoplasty and bunionectomy.
Abdominoplasty, or more commonly referred to as a “tummy tuck,” is a cosmetic surgical procedure in which excess skin and fat is removed from the abdomen, resulting in a smoother and firmer abdomen. A bunionectomy is a surgical procedure to remove a bunion from a patient’s foot. Depending on the complexity of these surgeries, some patients will experience severe postoperative pain.
18% Avenue
MB-102 is a chimeric antigen receptor (CAR) T therapy for acute myeloid leukemia (AML), blastic plasmacytoid dendritic cell neoplasm (BPDCN) and high-risk myelodysplastic syndrome (hrMDS).
View Clinical TrialAML, BPDCN, and hrMDS
Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells characterized by rapid growth of abnormal white blood cells that accumulate in the bone marrow. Although AML is rare, there were an estimated 19,520 new U.S. cases of AML in 2018 with an estimated five-year survival rate of 25%. Current treatment of relapsed or refractory AML with chemotherapy or hematopoietic stem cell transplantation is associated with low rates of complete response and considerable complications.
BPDCN is an ultra-rare disease and aggressive blood cancer with 500-1,000 patients per year in the U.S. and a median overall survival of 9-12 months.
CD123 is overexpressed on AML blasts and leukemic stem cell-enriched cell subpopulations compared to normal hematopoietic stem cells and myeloid progenitors, making CD123 an attractive target for T cell-based adoptive immunotherapy.
17% Mustang; 4.5% Royalty | 2.5% Equity Dividend
MB-101 is a chimeric antigen receptor (CAR) T therapy for glioblastoma (GBM).
View Clinical Trial View Clinical TrialGlioblastoma (GBM)
GBM is the most common brain and central nervous system (CNS) cancer, accounting for 45.2% of malignant primary brain and CNS tumors, 54% of all gliomas, and 16% of all primary brain and CNS tumors. There were an estimated 12,390 new GBM cases predicted in 2017 in the U.S. Malignant brain tumors are the most common cause of cancer-related deaths in adolescents and young adults aged 15-39 and the most common cancer occurring among 15-19-year-olds in the U.S. Although GBM is a rare disease (2-3 cases per 100,000 persons per year in the US and EU), it is quite lethal, with five-year survival rates historically under 10%. Standard of care therapy consists of maximal surgical resection, radiation and chemotherapy with temozolomide, which, while rarely curative, is shown to extend median overall survival from 4.5 to 15 months. GBM remains difficult to treat due to the inherent resistance of the tumor to conventional therapies.
17% Mustang; 4.5% Royalty | 2.5% Equity Dividend
MB-104 is a novel second-generation CS1-specific chimeric antigen receptor (CAR) T cell therapy for multiple myeloma (MM).
View Clinical TrialMultiple Myeloma (MM)
MM is a type of blood cancer that develops within bone marrow and affects plasma cells. Normal plasma cells produce antibodies that attack infections and diseases. When plasma cells become cancerous, however, they accumulate in the bone marrow and can cause severe pain and damage to the bone marrow. In addition, cancerous plasma cells will produce faulty antibodies, which make it harder for the body to fight off infections and diseases. Despite great advances in treatment, MM remains an uncured malignancy of plasma cells.
17% Mustang; 4.5% Royalty | 2.5% Equity Dividend
MB-106 is a CD20-specific chimeric antigen receptor (CAR) T Program for B-cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
View Clinical TrialB-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (CLL)
There are several forms of NHL, including follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma and small lymphocytic lymphoma, which account collectively for ~45% of all cases of NHL. Most types of NHL are incurable with available therapies, except for allogenic hematopoietic stem cell transplant (allo-SCT). More than 70,000 new cases of B-cell NHL are diagnosed each year in the United States, and more than 19,000 patients die annually due to this group of diseases.
17% Mustang; 4.5% Royalty | 2.5% Equity Dividend
MB-103 is a second-generation HER2-specific chimeric antigen receptor (CAR) T cell therapy for the treatment of glioblastoma (GBM) and metastatic breast cancer to brain.
View Clinical Trial View Clinical TrialGBM and Metastatic Breast Cancer to Brain
GBM is the most common brain and central nervous system (CNS) cancer, accounting for 45.2% of malignant primary brain and CNS tumors, 54% of all gliomas and 16% of all primary brain and CNS tumors. There were an estimated 12,390 new GBM cases predicted in 2017 in the U.S. Malignant brain tumors are the most common cause of cancer-related deaths in adolescents and young adults aged 15-39 and the most common cancer occurring among 15-19-year-olds in the U.S. Although GBM is a rare disease (2-3 cases per 100,000 persons per year in the U.S. and E.U.), it is quite lethal, with five-year survival rates historically under 10%. Standard of care therapy consists of maximal surgical resection, radiation and chemotherapy with temozolomide, which, while rarely curative, is shown to extend median overall survival from 4.5 to 15 months. GBM remains difficult to treat due to the inherent resistance of the tumor to conventional therapies.
HER2/neu (HER2) is a growth-promoting protein on the outside of all breast cells. HER2-positive (HER2+) breast cancer cells tend to grow and spread faster than other breast cancers. Breast cancer is the most commonly diagnosed cancer in women, with over 40,000 women in the U.S. expected to die from advanced metastatic disease annually. Approximately 20% to 25% of breast cancers overexpress HER2, which is an established therapeutic target of both monoclonal antibodies (mAbs) and receptor tyrosine kinase inhibitors.
17% Mustang; 4.5% Royalty | 2.5% Equity Dividend
MB-108 is a next-generation oncolytic virus (C134) that can replicate in tumor cells, but not in normal cells. Replication of MB-108 in the tumor itself not only kills the infected tumor cells but also causes the tumor cell to act as a factory to produce new virus.
View Clinical TrialGlioblastoma (GBM)
GBM is the most common brain and central nervous system (CNS) cancer, accounting for 45.2% of malignant primary brain and CNS tumors, 54% of all gliomas and 16% of all primary brain and CNS tumors. There were an estimated 12,390 new GBM cases predicted in 2017 in the U.S. Malignant brain tumors are the most common cause of cancer-related deaths in adolescents and young adults aged 15-39 and the most common cancer occurring among 15-19-year-olds in the U.S. Although GBM is a rare disease (2-3 cases per 100,000 persons per year in the US and EU), it is quite lethal, with five-year survival rates historically under 10%. Standard of care therapy consists of maximal surgical resection, radiation and chemotherapy with temozolomide, which, while rarely curative, is shown to extend median overall survival from 4.5 to 15 months. GBM remains difficult to treat due to the inherent resistance of the tumor to conventional therapies.
17% Mustang; 4.5% Royalty | 2.5% Equity Dividend
MB-105 is a second-generation PSCA-specific chimeric antigen receptor (CAR) T cell therapy for prostate, pancreatic, gastric and bladder cancers.
View Clinical TrialProstate, Pancreatic, Gastric and Bladder Cancers
Prostate cancer has an annual incidence of 164,000, pancreatic cancer has an annual incidence of 55,000, gastric cancer has an annual incidence of 26,000 and bladder cancer has an annual incidence of 81,000.
17% Mustang; 4.5% Royalty | 2.5% Equity Dividend
BAER-101 is a novel α2/3–subtype-selective GABA A positive allosteric modulator (“PAM”).
CNS Disorders
Central nervous system diseases, also known as central nervous system disorders, are a group of neurological disorders that affect the structure or function of the brain or spinal cord, which collectively form the central nervous system (CNS).
61% Baergic; 4.5% Royalty | 2.5% Equity Dividend
Dotinurad is being developed as a urate lowering therapy for the treatment of gout.
Rheumatology
Rheumatic diseases, sometimes referred to as musculoskeletal diseases, affect the joints, ligaments, tendons, bones or muscles. There are more than 200 distinct rheumatic diseases.
66% UR1 Therapeutics | 2.5% Equity Dividend
Mustang Bio, a Fortress partner company, is collaborating with Leiden University Medical Centre (LUMC) on the development of a novel ex vivo lentiviral gene therapy for the treatment of RAG1 severe combined immunodeficiency (“RAG1-SCID”)
RAG1-SCID
Severe combined immunodeficiency (SCID) due to complete recombinase-activating gene-1 (RAG1) deficiency is a rare, genetic severe combined immunodeficiency disorder due to null mutations in the RAG1 gene resulting in less than 1% of wild type V(D)J recombination activity. Patients present with neonatal onset of severe, recurrent fungal, viral and bacterial infections, as well as skin rashes, chronic diarrhea, failure to thrive and fever. Immunologic observations include profound T- and B-cell lymphopenia, low or absent serum immunoglobulins, and normal natural killer cell counts. As is the case with other types of SCID, RAG1-SCID is fatal in infancy unless immune reconstitution is achieved with hematopoietic stem cell transplantation (HSCT). RAG1-SCID Gene Therapy, developed by researchers at LUMC, has been exclusively licensed by Mustang Bio. Successful development of RAG1-SCID Gene Therapy may lead to its replacing HSCT in the treatment of the majority of RAG1-SCID patients.
17% Mustang; 4.5% Royalty | 2.5% Equity Dividend
Mustang Bio, a Fortress partner company, is collaborating with Mayo Clinic on the development of a novel technology that may be able to transform the administration of chimeric antigen receptor engineered T cell (“CAR T”) therapies and potentially be used as an off-the-shelf therapy for patients with hematologic and solid tumor malignancies.
Hematologic and Solid Tumor Malignancies
In Vivo CAR T Technology, developed by Larry R. Pease, Ph.D., principal investigator and former director of the Center for Immunology and Immune Therapies at Mayo Clinic, and exclusively licensed by Mustang Bio, is a new platform to administer CAR T therapy using a two-step approach. In the first step, an adenoviral vector is injected intradermally into the patient to drive the activation of resident T cells in nearby lymph nodes. In the second step, a viral CAR construct is injected directly into these lymph nodes. The viral construct infects the activated T cells and creates CAR T cells in vivo in the patient. These CAR T cells then migrate out of the lymph nodes into the circulation to proliferate and effect the killing of tumor cells. Successful development of the In Vivo CAR T Technology may lead to an off-the-shelf product with no need to isolate and expand allogeneic or autologous (patient-derived) T cells ex vivo.
17% Mustang; 4.5% Royalty | 2.5% Equity Dividend
AVTS-001 is an adeno-associated virus (AAV) gene therapy that restores lasting production of regulatory proteins, potentially providing a curative treatment for diseases with high unmet need.
AMD, PNH, and aHUS
54% Aevitas; 4.5% Royalty | 2.5% Equity Dividend
Adeno-associated virus (AAV)-based ATP7A is a gene therapy intended for use in combination with CUTX-101 for the treatment of Menkes disease and related copper transport disorders.
Menkes Disease
Menkes disease is an X-linked genetic disorder of copper transport caused by mutations of the ATP7A gene. Copper is an essential trace element required for human development and health. In Menkes disease, patients are born without the ability to absorb copper from diet, leading to severe developmental delays and significant neurological symptoms. Without treatment, Menkes disease could lead to death by three years of age. Currently, there is no FDA-approved therapy for treatment of Menkes disease.
72% Cyprium; 4.5% Royalty | 2.5% Equity Dividend
CK-103 is a BET inhibitor that is designed to inhibit BRD4, a member of the BET domain for cancer treatment.
Multiple Solid Tumors
19% Checkpoint; 4.5% Royalty | 2.5% Equity Dividend
CEVA-102 is the first cell product produced by CEVA-D and is being developed for the treatment of severe traumatic brain injury (TBI) in adults and children.
Traumatic Brain Injury (TBI)
TBIs are associated with 33% of all trauma-related deaths. There are no effective therapies to treat secondary brain injury and the post-injury response of central nervous system apoptosis and neuroinflammation.
78% Cellvation; 4.5% Royalty | 2.5% Equity Dividend
CK-302, an anti-GITR monoclonal antibody, is being developed as a novel treatment for patients with multiple solid tumors.
Multiple Solid Tumors
19% Checkpoint; 4.5% Royalty | 2.5% Equity Dividend
CK-303, an anti-CAIX monoclonal antibody, is being developed as a treatment for multiple solid tumors in patients.
Multiple Solid Tumors
19% Checkpoint; 4.5% Royalty | 2.5% Equity Dividend
ConVax is a universal recombinant modified vaccinia ankara viral vector vaccine designed to induce robust and durable humoral and cellular immune responses to cytomegalovirus (CMV).
Cytomegalovirus Prevention and Control
82% Helocyte; 4.5% Royalty | 2.5% Equity Dividend
CEVA-D is a novel bioreactor device that enhances the anti-inflammatory potency of bone marrow-derived cells without genetic manipulation, using wall shear stress (WSS) to suppress tumor necrosis factor-a (TNF-a) production by activated immune cells.
Traumatic Brain Injury (TBI)
TBIs are associated with 33% of all trauma-related deaths. There are no effective therapies to treat secondary brain injury and the post-injury response of central nervous system apoptosis and neuroinflammation.
78% Cellvation; 4.5% Royalty | 2.5% Equity Dividend
Targeted PNA sequence delivery to displace native DNA/RNA
75% Oncogenuity; 4.5% Royalty | 2.5% Equity Dividend
We have a library of valuable content and resources that provide in-depth knowledge on our product candidates and various therapeutic areas of interest.
View Publications